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Summary 
Background:  Surveillance colonoscopy is recommended for inflammatory bowel 
disease (IBD) patients with longstanding extensive colitis (LEC).  
Aims: To assess modalities and results of colonoscopic surveillance in a subset of 
CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in 
university French hospitals. 
Methods: Among 910 eligible patients with more than a 7-year history of extensive 
colitis at CESAME enrolment, 685 patients completed a questionnaire on surveillance 
colonoscopy and 102 were excluded because of prior proctocolectomy. Finally, 583 
patients provided information spanning a median period of 41 months (IQR 38-43) 
between cohort enrolment and the end of follow-up. Details of the colonoscopic 
procedures and histological findings were obtained for 440 colonoscopies in 270 
patients. 
Results: Only 53.5% (n=312) of the patients with LEC had at least one surveillance 
colonoscopy during the study period, with marked variations across the 9 
participating centres (27.3% to 70.0%, p= < 0.0001). Surveillance rate was 
significantly lower in Crohn’s colitis than in ulcerative colitis (UC) (47.6% vs 68.5%, 
p=< 0.0001). Independent predictors of colonoscopic surveillance were male sex, UC 
IBD subtype, longer disease duration, previous history of CRC, and disease 
management in a centre with large IBD population. Random biopsies, targeted 
biopsies and chromoendoscopy were performed during respectively 70.7%, 26.6 and 
30.0% of surveillance colonoscopies. Two cases of high-grade dysplasia were 
detected in patients undergoing colonoscopic surveillance. Two advanced-stage 
CRC were diagnosed in patients who did not have colonosocopic surveillance. 
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Conclusions: Colonoscopic surveillance rate is low in IBD patients with longstanding 
extensive colitis. 
 
Key words: 
Inflammatory bowel disease; Colorectal cancer; Colonoscopic surveillance 
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Patients with longstanding extensive ulcerative colitis (UC) are at high risk of 
developing colonic epithelial dysplasia and carcinoma.1 Growing evidence suggests 
that the same is true of patients with longstanding extensive Crohn’s colitis.2, 3 Two 
interventions are currently used in an attempt to reduce mortality by colorectal cancer 
(CRC) in these patients, namely colonoscopic surveillance and chemoprevention with 
oral 5-aminosalicylates (5-ASA). Colonoscopic surveillance has not been shown to 
reduce mortality among patients with extensive colitis, but it does tend to allow 
cancer to be detected at an earlier stage, thereby improving the prognosis.4 There is 
good international agreement that patients with inflammatory bowel disease (IBD) 
and extensive colitis should have surveillance colonoscopy every 1-3 years, generally 
starting 7-10 years after IBD onset, or from IBD diagnosis in patients with associated 
primary sclerosing cholangitis.4-11 Extensive UC is defined on the basis of the 
cumulative macroscopic or microscopic extent of the disease proximal to the splenic 
flexure.7, 12 Extensive Crohn’s colitis is arbitrarily defined as cumulative endoscopic 
involvement of more than one-third of the colon.2, 7 Surveillance colonoscopy should 
ideally be performed outside periods of disease activity and with good bowel 
cleansing, and should include multiple random biopsies or targeted biopsies after 
chromoscopy. 
Despite this solid consensus, questionnaire-based studies have revealed suboptimal 
awareness and implementation of guidelines by gastroenterologists in various parts 
of the world.13, 14 In addition, the degree of information, acceptance and adherence to 
surveillance programs among patients at risk is unknown. Population-based studies 
have shown poor implementation of endoscopic surveillance among IBD patients at 
very high risk of colorectal cancer because of associated primary sclerosing 
cholangitis.15 A low prevalence of colorectal surveillance of patients with longstanding 
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UC belonging to an integrated health care delivery system was recently reported,16 
but there are no published reports of the implementation and yield of surveillance 
colonoscopy in patients with either UC or Crohn’s disease who are at a high risk of 
colorectal cancer because of longstanding extensive colitis. We therefore conducted 
an ancillary study nested in the CESAME project in order to assess the 
implementation, modalities and yield of surveillance colonoscopy in a cohort of IBD 
patients with longstanding extensive colitis. We also compared the incidence of 
advanced-stage neoplasias in surveyed and non-surveyed patients, and examined 
the relative proportions of patients receiving surveillance colonoscopy and/or 
chemoprevention with 5-ASA. 
 
METHODS 
Study design 
The study was nested in the CESAME project, which is described in detail 
elsewhere.17 In brief, 19 486 IBD patients (1159 with Crohn’s disease and 7727 with 
UC or unclassified IBD) were enrolled between May 2004 and May 2005 in a French 
nationwide cohort by 680 gastroenterologists, who r ported all incident high-grade 
dysplasias, cancers and deaths up to 31 December 2007. At enrolment, the 
gastroenterologists recorded the patient’s age, gender, IBD subtype, year of 
diagnosis and cumulative extent of disease.  Cumulative involvement of the colon in 
UC and Crohn’s colitis was arbitrarily categorized as extensive when the cumulative 
percentage of the colonic surface ever involved, estimated by the investigating 
gastroenterologist, exceeded 50%. CESAME patients meeting this criterion also 
fulfilled the definition of extensive colitis stated in surveillance colonoscopy 
guidelines.2, 7, 12  
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This nested ancillary study was initiated in September 2008. Patients enrolled in the 
CESAME cohort were eligible for this study if they belonged to the CESAME cohort 
and met the following criteria: IBD duration longer than 7 years at the outset of the 
CESAME observation period; extensive colitis at entry; and enrolment to the cohort 
by a gastroenterologist working full-time in one of the 9 Paris area university hospital 
gastroenterology units participating in the CESAME project. All 910 patients who met 
these criteria were sent a questionnaire covering the following items: previous history 
and type of any colectomy, current treatment with corticosteroids, thiopurines, 
methotrexate or TNF antagonists, duration and modalities of any treatment with oral 
5-ASA; and number of coloscopies between May 2004 (first inclusions in the 
CESAME cohort) and 31 December 2007. Patients who had at least one 
colonoscopy were asked to complete an additional sheet for each colonoscopy, 
covering where the colonoscopy was performed and the medical indication (flare, 
disease assessment before a change of treatment, or cancer screening). The 
questionnaire was accompanied by an explanatory letter and a pre-paid envelope to 
return either the questionnaire or a refusal form. Patients who did not return the 
completed questionnaire or the refusal form after one month were contacted by 
telephone. If during the conversation they consented to participate, they were 
interviewed by phone on the same items as those contained in the written 
questionnaire. The protocol was approved by Comité Consultatif sur le Traitement de 
l’Information en matière de Recherche dans le domaine de la Santé, and the study 
was authorized (n° DR-2010-019) by Comission Nationale de l’Informatique et des 
Libertés.  
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Patient selection and analysis of colonoscopy reports 
Among the 910 patients eligible for the study, 10 died before the questionnaires were 
sent out, and 34 had no known address (fig. 1). Eight hundred and sixty-six 
questionnaires were sent out. Nineteen patients refused to participate and 162 did 
not respond by mail or by phone.  A total of 685 patients answered the questionnaire, 
representing a 79% participation rate. There was no statistically significant difference 
in gender, age or the IBD subtype between patients who answered the questionnaire 
and those who did not. Among the 685 patients who answered the questionnaire, 
102 were excluded because of a prior history of proctocolectomy. The final study 
population consisted of 583 patients.  
Among the 312 patients who mentioned at least one surveillance colonoscopy in the 
questionnaire, 282 had their examination performed in the endoscopy department of 
one of the nine participating centres. We were able to obtain a copy of the 
endoscopic and histological reports of 440 colonoscopies performed in 270 patients. 
A standardized report form was used to collect the following details: quality of bowel 
preparation (categorized as satisfactory or unsatisfactory); thoroughness of 
exploration of the colonic segments to be explor d; presence of macroscopic 
inflammatory lesions (at least frank erythema); use of chromoscopy; and collection of 
random biopsies (at least 4 per segment) and/or targeted biopsies. 
We were thus able to validate the information given by the patients on the number, 
indications and modalities of their colonoscopies, and found an overall concordance 
exceeding 90% for each item. In case of disagreement we kept the information 
contained in the endoscopic reports.   
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Data analysis 
Taking into account the length of the study period (median 41 months, minimum 31 
months) and published guidelines on surveillance colonoscopy, all the patients with 
longstanding extensive colitis should have had at least one surveillance colonoscopy, 
i.e. a dedicated cancer screening colonoscopy, during the study period. Patients who 
had at least one surveillance colonoscopy during the study period formed the 
“surveyed” population, and the remaining patients the “non-surveyed” population. 
Patients prescribed chemoprevention with 5-ASA during the study period formed the 
population of patients exposed to oral 5-ASA. Patients with unclassified IBD were 
pooled with UC patients for analysis. 
Statview® statistical software (version 5.0, SAS Institute Inc., Cary, NC) was used to 
analyse the data. Fisher’s exact test was used to compare the proportions of 
surveyed and non-surveyed patients with each IBD subtype, and to identify a 
possible correlation between colonoscopic surveillance and 5-ASA chemoprevention. 
The Chi-square test was used to compare the proportions of surveyed patients 
across the study centres. The following 8 variables were tested as possible 
independent predictors of colonoscopic surveillance: gender; IBD subtype; age; 
disease duration; previous personal history of colorectal cancer; sustained? 
treatment with 5-ASA; the number of IBD patients followed per investigator; and the 
number of IBD patients followed per centre. The 4 continuous variables were 
dichotomized around the median. All 8 variables were first separately compared 
between surveyed and non-surveyed patients by using Fisher’s exact test, then 
variables with p values below 0.20 were entered in a multivariate logistic regression 
model using a backward stepwise procedure. The final step retained independent 
factors with P values below 0.05 in a two-tailed test. 
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RESULTS 
Overall surveillance rate and patients’ baseline characteristics according to 
surveillance status 
Characteristics of the 583 patients who answered the questionnaire by mail (n=351) 
or by phome (n=232) and who had no history of proctocolectomy are shown in table 
1. The surveyed population consisted of 310 patients (53.2%) who had at least one 
surveillance colonoscopy during the study period (median 41, IQR 38-43). 
Respectively 165, 104, 33, 8 and 1 patients had 1, 2, 3, 4 and 5 surveillance 
colonoscopies. One patient had 7 surveillance endoscopies during the study period, 
to monitor unifocal low-grade dysplasia.  
Factors influencing surveillance 
The monitoring rate was significantly higher among patients with UC or unclassified 
IBD than among patients with Crohn’s disease (68.5% versus 47.6%, p<0.0001). 
Considering all IBD subtypes together, surveillance implementation varied widely 
across the study centres (27.3 to 70%, p < 0.001 (fig 2)). Independent predictors of 
surveillance (table 2) were male gender, UC, longer disease duration, a previous 
history of colorectal cancer, and management in a centre with a large IBD patient 
population.  
Colonoscopic procedures and pathology reports: 
We were able to analyze 440 reports of colonoscopies performed in 270 patients, 
along with the corresponding pathology reports. The quality of bowel preparation was 
specified in 82.7% of colonoscopy reports and was considered by the endoscopist as 
satisfactory and unsatisfactory in 83.8% and 16.2% of cases, respectively. 
Exploration of anatomically evaluable colonic segments was complete in 96.6% of 
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cases. Endoscopic evidence of mild inflammation (frank erythema or multiple 
pseudopolyps) or active inflammation (ulceration) was mentioned in respectively 
30.0% and 5.2% of reports. At least one biopsy was performed in 97.3% of 
procedures, and consisted of random biopsies (at least 4 biopsy samples per colonic 
segment), random biopsies plus targeted biopsies, or targeted biopsies alone, in 
respectively 72.6%, 26.5% and 0.9% of cases. Chromoendoscopy was performed 
during 30.0% of colonoscopies. The pathology reports mentioned the presence and 
absence of active microscopic inflammation and any type of dysplasia in respectively 
94.7% and 77.7% of cases. Fourteen cases of flat low-grade dysplasia were found in 
12 patients (4.4%), of whom 5 were exposed to 5-ASA at the time of diagnosis of 
dysplasia. Twelve adenoma-like masses with low-grade dysplasia were found in 11 
patients (4%), of whom 6 were exposed to 5-ASA at the time of diagnosis of 
dysplasia. 
 
Incident advanced-stage neoplasias 
Four patients in this ancillary study, all with Crohn’s colitis, were diagnosed with 
advanced-stage colonic neoplasia during the study period: two advanced-stage 
colorectal cancers (T4N0M0 and T4N2M0) were diagnosed in non-surveyed patients. 
The first patient was a 26-year man with a 10-year history of extensive Crohn's colitis 
and the second a 30-year female with a 16-year history of extensive Crohn's colitis.  
Two cases of high-grade dysplasia were detected in two surveyed patients. The first 
patient was a 56-year man with a 10-year history of extensive Crohn's colitis and had 
a flat dysplasia.  The second patient was a 31-year man with a 15-year history of 
extensive Crohn's colitis in whom a dysplasia-associated lesion or mass was 
diagnosed. After confirmation of dysplasia by a second independent pathologist, both 
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patients underwent coloproctectomy. Colon cancer was found on the colectomy 
specimen of the first patient with flat high-grade dysplasia (stage T2N0M0). High-
grade dysplasia was confirmed on the colectomy specimen of the second patient with 
the dysplasia-associated lesion or mass, without additional advanced-stage 
neoplasia. 
 
 
Correlation between colonoscopic surveillance and chemoprevention with 5-
ASA 
Continuous oral 5-ASA was prescribed to 37.4% of the 583 patients during the study 
period. The distribution of patients who received colonoscopic surveillance and/or 
treatment with 5-ASA is shown in table 3 according to the IBD subtype. There was a 
significant link between surveillance and treatment with 5-ASA (p=0.0001), with a 
trend towards being either both surveyed and treated with 5-ASA, or non-surveyed 
and untreated. When considering together the two types of IBD, one third of the 
patients escaped both to endoscopic surveillance and treatment with 5-ASA.  
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DISCUSSION 
We observed low implementation of endoscopic surveillance in a cohort of IBD 
patients at high risk of colorectal cancer and managed in French university hospitals. 
We also observed massive inter-centre variations and a large proportion of non-
surveyed patients: one-third of patients with ulcerative colitis and more than one-half 
of patients with Crohn’s colitis were not surveyed. Some cases of advanced 
colorectal neoplasias were diagnosed in non-surveyed patients. 
This study was initially based on a self-reporting patient questionnaire, with a 
potential memory bias, representing therefore two important potential methodological 
limitations of the work. However, the completion rate of the questionnaire was 79% 
(81% when including patients who responded that they refused to participate), which 
is in the upper range of patient questionnaire ratings.18 The secondary exclusion of 
11% of the patients because of previous proctocolectomy, thus with no actual 
eligibility for surveillance, did not impact on the quality of the results. Regarding 
memory bias, it is very unlikely that patients did not remember that they underwent 
one or several colonoscopies during the previous three years. We had also the 
opportunity through the study of endoscopic reports to validate the information given 
by the patients on the number, indications and modalities of their colonoscopies, and 
found an overall concordance exceeding 90% for each item. Finally, in the first 
author’s centre, analysis of the local endoscopic files showed that surveillance was 
substantially less frequent among patients who did not answer the questionnaire 
(data not shown), suggesting that our results likely overestimate the implementation 
of endoscopic surveillance. So the main result of our work (low prevalence of 
surveillance) would have been amplified in the case of full completion rate of the 
questionnaire. We obtained details on colonoscopy in only 82% of surveyed patients, 
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but the main purpose of our study was not assess the yield of the surveillance 
according to colonoscopy quality, and the number of detected neoplasias was too 
low to properly assess the impact of different biopsy modalities or exposure to 5-ASA 
on the rate of detected lesions.  
In comparison with previous reports on the prevalence of colonoscopic surveillance in 
IBD patients at risk for colorectal cancer,16 our study is the first to restrict the analysis 
to patients at highest risk (i.e. with longstanding extensive colitis), to simultaneously 
address the question patients with ulcerative colitis and Crohn’s disease, and to give 
the data on incident colorectal cancers in  surveyed and non-surveyed patients. 
Until now, information on gastroenterologists’ adherence to international guidelines 
on endoscopic surveillance of IBD patients at risk of colorectal cancer, and on the 
management of dysplasia, has mainly been based on gastroenterologists’ own 
estimates.5, 14, 19, 20 The results of these studies showed that knowledge and 
understanding of the pathogenesis and management of IBD-associated colorectal 
neoplasias was unsatisfactory, but almost all the interviewed gastroenterologists 
declared that they performed endoscopic surveillance in the majority of their IBD 
patients at risk. Similarly, a clinical practice survey of patients already enrolled in 
surveillance programs in a tertiary care centre suggested good implementation of 
relevant guidelines.21  
In order to obtain a more realistic view of the situation, we assessed the 
implementation of surveillance colonoscopy by adopting an at-risk population-based 
approach. Endoscopic surveillance has previously been shown to be suboptimal in a 
subgroup of IBD patients at very high risk of colorectal cancer due to associated 
primary sclerosing cholangitis.15 Likewise, a low rate of surveillance colonoscopy was 
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found in North California patients with at least an 8-year history of UC and belonging 
to an integrated healthcare delivery organization.16   
We based our study on the CESAME observational cohort, selecting patients at high 
risk of colorectal cancer and managed in 9 university hospitals in the Paris area. 
Implementation of endoscopic surveillance was found to be suboptimal, particularly in 
Crohn’s disease patients, even though all the participating centres belong to GETAID 
and are therefore involved in promoting IBD education.  
This incomplete endoscopic surveillance may be due to factors related to the patients 
and/or their physicians. Patients may be reluctant to participate in surveillance 
programs because they consider endoscopy to be unpleasant and risky, but UC 
patients undergoing surveillance did not express increased anxiety or general health 
impairment compared to a control population of UC patients.22 It is crucial to inform 
IBD patients of the risk of CRC and the modalities and expected results of 
surveillance. A survey conducted in the late 1990s suggested that patients were 
adequately informed on the risk of colorectal cancer but not on the effectiveness and 
modalities of surveillance programs,23 including the safety of colonoscopy.24  The 
massive inter-centre variations observed in our study point rather to a role of 
physician-related factors in suboptimal surveillance, and particularly poor awareness 
of the benefits of surveillance.  
Interestingly, the surveillance rate was higher among males than females in our 
study, while a similar non-significant trend towards a better surveillance in males was 
reported in the study by Velayos et al.16 We have no explanation for that. In studies 
assessing the predictors of participation in screening programs for sporadic colorectal 
cancer, an increased prevalence of sigmoidoscopic surveillance25 and a trend 
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towards a preference for endoscopy rather than for faecal tests26 were also reported 
in males.   
More than half the patients with extensive Crohn’s colitis were not adequately 
surveyed, whereas all the incident colorectal cancers were diagnosed in patients with 
Crohn’s disease. Inflammation-related cancers arising in Crohn’s colitis and UC have 
a similar distribution and histology (synchronous, right-sided, colloid contingent), and 
tend to be associated with coexisting foci of flat dysplasia in both settings.27, 28 Similar 
incidence rates of colorectal cancer have also been reported in UC and Crohn’s 
colitis,27-30 although this feature was restricted in some referral centre cohorts of 
patients wiith Crohn’s disease to those  with UC-like lesions.31 In the CESAME 
cohort, the rates of excess colorectal cancer were similar in UC and Crohn’s disease 
patients with longstanding extensive colitis.3 Thus, there is no theoretical reason to 
adapt endoscopic surveillance to the IBD subtype. Published surveillance guidelines 
refer currently to IBD colitis5-8, 10 or UC alone,9 but there are no statements on 
colonoscopic surveillance in the most recent guidelines restricted to Crohn’s 
disease.32 Second, the definition of extensive Crohn’s colitis2, 7 is not as consensual 
as that of extensive UC and does not appear in the Montreal classification. Finally, it 
may be more difficult to appreciate the cumulative percentage of inflamed mucosa in 
multifocal Crohn’s colitis than in UC-like Crohn’s colitis or UC.  
Chemoprevention is another approach to reducing the risk of colorectal cancer in 
patients at risk, that has been considered by some authors as an alternative to 
surveillance,33 but we found that respectively 20% and 40% of UC and Crohn’s 
patients at risk escaped both control measures. The efficacy of treatment with 5-ASA 
is controversial in IBD patients at risk, and especially those with Crohn’s disease, 
although the cost-effectiveness of combined methods has been recently estimated.34 
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Whatever the final position of the gastroenterological community, the suboptimal and 
highly variable implementation of both control methods observed here in real-life 
practice is unacceptable and calls for urgent corrective measures. In addition to 
better education of gastroenterologists and patients, elaboration of specific guidelines 
in Crohn's disease, systematic mailing proposal for colonoscopic surveillance to 
patients at risk, and greater implication of patient associations and health authorities 
could be considered. 
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Figure legends 
 
Figure 1. Flow chart  
 
 
Figure 2. Proportion of IBD patients undergoing colonoscopic surveillance according 
to IBD subtype (UC, ulcerative colitis; IBDU, IBD unclassified) and study centre 
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Table 1 Characteristics of the study population (n=583) according to surveillance status during the 
study period 
 Total (n=583) Surveyed*(n=312 ) Non-surveyed (n=271) 
Male sex (%) 237 (40.6%) 143 (45.8%) 94 (34.7%) 
Age at inclusion in the study † 40 (32-52) 41 (33-53) 38 (31-49) 
IBD subtype 
     Crohn’s disease 
     UC or IBD, unclassified 
 
418 (71.7%) 
165 (28.3%) 
 
199 (63.8%) 
113 (36.2%) 
 
219 (80.8%) 
52 (19.2%) 
IBD duration at inclusion (years)† 13.8(10.5-
19.5) 
14.9 (11.1-20.6) 12.6 (9.6-18.6) 
Previous history of colorectal cancer 16 (2.7%) 15 (4.8%) 1 (0.3%) 
Previous colectomy 
     Segmental colectomy 
     Subtotal colectomy 
 
92 (15.8%) 
87 (14.9%) 
 
35 (11.2%) 
44 (14.1%) 
 
57 (21%) 
43 (15.9%) 
Study period (months)† 41 (38-43) 41 (38-43) 42 (38-43) 
Treatment at inclusion (%) 
      Steroids 
     Thiopurines or Methotrexate 
     Anti-TNF 
 
23 (3.9%) 
227 (38.9%) 
90 (15.4%) 
 
11 (3.5%) 
120 (38.5%) 
41 (13.1%) 
 
12 (4.4%) 
107 (39.5%) 
49 (18.1%) 
Any oral 5-ASA throughout the study (%) 
     Median dose of 5-ASA (g/day)† 
     Treatment duration with 5-ASA prior  
      to the study (years) † 
218 (37.4%) 
2 (1.6-3) 
7 (1-15) 
139 (44.6%) 
2 (2-3) 
8 (2-16) 
79 (29.1%) 
2 (1.5-3) 
6 (1-14) 
* At least one surveillance colonoscopy during the study period 
† Median (IQR) 
IBD, inflammatory bowel disease 
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Table 2. Independent predictors of colonoscopic surveillance  
 Odds ratio 95% CI p 
Male sex 1.60 1.12-2.27 0.009 
IBD subtype: UC+ IBDu 2.13 1.41- 3.22 0.0003 
 
IBD duration at CESAME inclusion (per 
additional year) 
1.04 1.01-1.07 0.009 
 
Previous history of CRC 17.50 2.22-138.10 0.006 
 
Large number of patients per centre  (≥ 
29 patients) 
1.89 1.10-3.23 0.02 
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Table 3. Distribution of the study population (n=583) according to colonoscopic surveillance status and 
treatment with any oral 5-ASA throughout the study period  
 All patients (n= 583) UC or IBD, unclassified (n=165) Crohn’s colitis (n= 418) 
 Surveyed 
(n=312) 
Non-surveyed 
(n= 271) 
Surveyed 
(n=113) 
Non-surveyed  
(n= 52) 
 
Surveyed  
(n= 199) 
Non-surveyed  
(n= 219) 
5-ASA (%*) 139 (23.8%) 79 (13.6%) 76 (46.1%) 22 (13.3%) 63 (15.1%) 57 (13.6%) 
No 5-ASA (%) 173 (29.7%) 192 (32.9%) 37 (22.4%) 30 (18.2%) 136 (32.5%) 162 (38.8%) 
* Percentages refer to the total of patients with the IBD subtype 
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Figure 1 
 
 
 
 
 
 
866 questionnaires sent 
19 pts refused to participate 
162 pts did not answer 
685 questionnaires completed 
102 pts with previous 
coloproctectectomy  
583 pts studied 
910 patients (pts) eligible 
10 pts died 
34 addresses lacking 
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EDITOR'S COMMENTS TO AUTHOR: 
Very interesting (and worrying study). It would be interesting to know what "corrective 
measures" you would propose to implement.  
Consider adding in the discussion a paragraph about strength and weaknesses of 
the study. 
We added some suggestions for "corrective measures" in the last paragraph of the 
discussion. We also added two paragraphs in the discussion (second and third 
paragraph) considering the weaknesses and strengths of the work.  
 
 
 
REVIEWERS' COMMENTS TO AUTHOR: 
 
Reviewer: 1 
Comments for Transmission to the Authors  
Although AP&T discourages a geographical location in the Title, I think the country of 
the study should be mentioned in the Summary. 
Done 
AP&T has a specific style for the Summary: Background, Aim, Methods, Results, 
Conclusions - all in <250 words.  
Done 
In the past few years, AP&T has published several relevant papers about 
colonoscopy, which could augment the Discussion. 
Two interesting papers from AP&T are now cited in the discussion 
 
Reviewer: 2 
Comments for Transmission to the Authors  
In the present study the authors assessed modalities and results of colonoscopic 
surveillance in a subset of CESAME cohort patients at high risk of CRC. 
The issue is an interesting one. Nevertheless, the main bias of the study is 
represented by the observation that a high proportion of patients were excluded from 
the analysis and that reports of colonoscopies were available only for a proportion of 
patients The following major and minor issues should be addressed before 
acceptance of the manuscript.   
 
Major comments 
1. Study Population. Table 1 clearly shows that UC and CD patients were differently 
represented among monitored and unmonitored patients. In particular, in CD there 
was a higher proportion of unmonitored patients (81%)(p=?). Moreover, the 
monitoring rate was higher in UC vs CD (p<0.0001)(pag. 10). This different 
distribution of patients may not allow proper comparison between CD and UC. Please 
discuss this finding.  
We are not sure to have understood the reviewer's comment. May be there was an 
ambiguity in the "monitored" term so we replaced it by "surveyed". Regarding the 
completion rate of the questionnaire, there was no difference between Crohn's 
disease and ulcerative colitis. Among the patients finally studied, the surveillance rate 
was higher in ulcerative colitis than in Crohn's colitis, which is an important result of 
the study. The univariate statistical test was given in the text of the result section of 
the original version (first sentence of the paragraph entitled "factors influencing 
surveillance"). The role of the other factors on the surveillance rate was assessed by 
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multivariate analysis (Table 2), which is the appropriate method to assess the 
independent individual impact of other factors    
 
 
2. The proportion of patients assuming any oral 5-ASA was also higher in monitored  
      vs unmonitored patients (44.6% vs 29.1%; p=?). This observation may also  
      influence the rate of dysplastic/neoplastic lesions: please discuss this issue.  
The reviewer is right. We wrote in a dedicated paragraph of the result section of the 
original manuscript that "There was a significant link between surveillance and 
treatment with 5-ASA (p=0.0001), with a trend towards being either both surveyed 
and treated with 5-ASA, or non-surveyed and untreated." The number of incident 
neoplasias according to the exposure status to 5-ASA is now given in the revised 
version of the manuscript. But we think that the influence of exposure to 5-ASA o the 
incidence of neoplastic lesions cannot be properly assessed statistically given the low 
number of events. 
 
3. Methods: page 7: 910 patients who met criteria were sent a questionnaire covering 
several items regarding clinical characteristics of the disease. The bias of a 
retrospective analysis reported in a questionnaire should be reported and discussed.   
Patients excluded for previous coloproctectomy were not eligible for the study (no 
colon, no surveillance), so this exclusion did not impact on the quality of the results. 
The questionnaire completion rate was about 80% and there was no difference in the 
completion rate according to IBD subtype (Method section). The memory bias is a 
potential important one, but we had the opportunity to cross-validate self-reporting 
data in the majority of the patients through the access to endoscopic reports. This is 
discussed in the revised paper in the second and paragraph of the discussion.     
 
4. The major bias of the study is represented by the retrospective analysis of the data 
and by the high rate of patients excluded from the analysis (from 910 to 583 
patients). Moreover among these 583 patients, endoscopic reports were obtained 
only for 440 colonoscopies performed in 270 patients. Details of colonoscopy 
(including bowel preparation, reported only in 82% pts with endoscopic reports, 
coecal intubation, etc were therefore missing in a high proportion of patients). Please 
comment on that in the discussion. 
5. The number and site of the biopsies differed among patients, thus leading to 
possible differences in terms of diagnosis of dysplasia. Please comment on that. 
4 and 5. Our study was focused on the prevalence of the surveillance and the 
identification of the factors associated with a low rate of surveillance. The reviewer is 
right to point the incomplete data collection in the section of the work devoted to the 
modalities of colonoscopies. So we chose not to speculate in the result or in the 
discussion section on the relationship between colonoscopy modalities and incidence 
of dysplastic lesion. In addition, the number of events was too low to perform an 
accurate analysis. 
 
Minor comments 
 
1. Figure 1: excluded due to “previous proctocolectomy” and not “colectomy”, please 
modify  (page 8). 
Done 
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2. The percentage of patients not reporting the questionnaire but replying only by 
telephone should be reported in the results section and also discussed. 
The number of patients contacted by phone was added in the revised manuscript. 
The questionnaire of the paper version and of the phone call was the same and the 
validity of declarative data is discussed in the second paragraph of the discussion.  
 
3. Results regarding the detection of dysplasia (page 11) should be also reported in 
patients monitored vs unmonitored and in patients with vs without 5-ASA treatment. 
In the non-surveyed (non-monitored) patients, only colorectal cancers were 
diagnosed. In the surveyed patients with incident dysplasia, we added the 
information on the proportion of patients exposed to 5-ASA. 
 
4. Please provide clinical details of patients developing colorectal cancer and 
dysplasia (age, disease duration, use of 5-ASA, disease extent). 
We provide in the revised version clinical details in all the patients who developed 
colorectal cancer or high-grade dysplasia.      
 
 
 
Reviewer: 3 
Comments for Transmission to th  Authors  
Beaugerie and colleagues performed a nested study within the CESAME cohort to 
assess use of surveillance colonoscopy in long-standing (>7 years) colitis (CD and 
UC).  They  
found that a significant number of pts did not have "adequate" surveillance.  This 
analysis is of interest, not just because of the importance of the CESAME cohort and 
follow-up, but also because it contributes to the understanding that physicians are not 
performing surveillance as recommended in guidelines.  The statement that the 
surveillance is "suboptimal" might be stretching it a bit, as we don't actually know 
what "optimal" surveillance really is - from a mortality benefit.  
 
Additional strengths of the study includes that it reflects practice within the northern 
France gastro community, with a very high response rate to the surveys.  In addition, 
there was a high degree of correlation b/w survey responses and chart review. 
 
The concerns I raise include the following:   
1. Can you really conclude that surveillance was "suboptimal" based on these 
results?  I would suggest what you've shown is that surveillance is not following 
accepted guidelines in many patients, but to call it suboptimal suggests you've 
actually shown a significant difference in outcomes, which I don't think you have.  If 
you were going to assess differences in outcomes of the monitored and unmonitored 
groups, you need to control for risks of neoplasia, including degree of inflammation, 
which is not captured in this database.  Therefore, I'd suggest softening the 
conclusions and the title to more accurately reflect what is shown here- that 
guidelines are infrequently followed. 
The reviewer is right. We replaced the term "suboptimal" with the more neutral term 
"low prevalence of". 
 
2.  What were the reasons for colectomy in the 102 patients who were eligible for this 
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study but couldn't participate?  Were any of these due to dysplasia or cancer?  If so, 
that would suggest that there may be a survival bias or that the approach to 
surveillance is more effective than acknowledged. 
Unfortunately, the indication of the proctocolectomy was not an item of the survey so 
we have not this information. 
 
3.  you refer to the patients on 5- ASA as having been "prescribed" 
chemoprevention.  Was that really the reason for it, or are you assuming so, but 
actually the 5-ASA was being given for treatment?  Consider modifying this language. 
The reviewer is right. We have no data on the indication of the treatment with 5-ASA. 
We replaced the terms "chemoprevention" and "prescription" by "treatment with" and 
"exposition". 
 
4.  The group with previous colorectal cancer is of interest - if UC, would presume 
that they had a proctocolectomy, so what exams were they receiving??  If CD, would 
suspect that the area of colitis was resected in such patients, so perhaps they should 
not have inflammation any longer (and might not undergo the usual surveillance)?  I'd 
suggest excluding these 
patients from your analysis given the potential biases that they may cause. 
Patients with previous proctocolectomy were excluded from this work. The 14 
patients with previous colorectal cancer (11 Crohn, 3 UC) had a segmental colectomy 
or a subtotal colectomy with subsequent surveillance of the remaining segments. 
They were better surveyed than the rest of the patient population (Table 3), which is 
an interesting result. As we performed a multivariate analysis for assessing the other 
factors, we are not sure that exclusion of patients with previous cancers is 
appropriate.   
 
5. would be interesting to see the survey- perhaps as an online appendix 
The original survey was uploaded beside the manuscript.  
 
6.  the gender differences (Males surveyed more than females) is fascinating and I 
appreciate the discussion.  Why?  was their disease more active?  is that what drove 
this?  (some gender based studies have shown that males are less likely to get 
mucosal healing and other studies have shown that males are at higher risk for 
cancer). 
We extended speculation and references on male predominance to other contexts of 
colonoscopic surveillance. 
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SECCIRC  
ENQUETE DE PRATIQUE DE LA COLOSCOPIE DANS LES MICI 
NUMERO D’ANONYMAT 
 
 
 
Vous vous apprêtez à répondre à un questionnaire dans le cadre d’une enquête sur la réalisation 
des coloscopies dans les MICI (Maladies Inflammatoires Chroniques de l’Intestin).  
Un grand MERCI pour votre collaboration. 
 
Pour toutes les questions suivantes, merci d’entourer la ou les réponses vous 
concernant : 
 
 
A. De quel type de maladie inflammatoire de l’intestin souffrez-vous ? 
 
0. Je ne sais pas  
1. Recto-colite hémorragique (RCH) 
2. Maladie de Crohn  
3. Colite inflammatoire sans que l’on sache s’il s’agit d’une maladie de Crohn ou 
d’une RCH 
 
 
B. Avez-vous déjà été opéré du côlon (gros intestin) 
 
0. non, jamais 
1. oui 
 
 
C. * Si vous avez déjà été opéré du côlon (gros intestin), quel type d’opération avez-
vous eue ? 
 
0. on a enlevé tout le côlon et le rectum avec une anastomose iléo-anale et la 
confection d’un réservoir avec l’intestin grêle 
1. on a enlevé tout le côlon et le rectum avec une poche définitive 
2. on a enlevé tout le côlon mais pas le rectum 
3. on a enlevé seulement une partie du côlon 
4. je ne sais pas 
 
 
 
* Si vous avez répondu 2, 3 ou 4 à la question précédente C, merci de répondre aux questions 
suivantes :  
 
 
* Si vous avez répondu 0 ou 1 à la question précédente C (ablation totale du côlon et du rectum), la 
question de la réalisation de coloscopies ne se pose pas de la même façon chez vous, il n’est donc pas 
nécessaire que vous répondiez aux questions suivantes. Merci d’avoir pris le temps de remplir et de 
nous renvoyer malgré tout ce questionnaire.  
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D. Quel(s) traitement(s) recevez vous actuellement ? (plusieurs réponses possibles, 
entourez les réponses exactes) 
 
0. Je ne reçois actuellement aucun traitement  
1. Comprimés (ou gélules ou granulés) de dérivés 5 aminosalicylés (5ASA) : Pentasa, 
Rowasa, Dipentum, Fivasa ou Salazopyrine 
2. Lavements de Pentasa ou de Quadrasa 
3. Suppositoires de Pentasa, Rowasa, ou Fivasa 
4. Comprimés de Cortisone : solupred, cortancyl, prednisone ou prednisolone  
5. Imurel, Azathioprine, Purinethol, Méthotrexate 
6. Remicade, Humira, Cimzia 
7. Autre traitement pour la MICI: lequel……………………………… 
 
 
E. Si vous êtes actuellement traité par comprimés (ou gélules ou granulés) de 
Pentasa, Rowasa, Dipentum, Fivasa ou Salazopyrine, depuis quand prenez vous ce 
traitement de façon continue ? (mois et année ou année seule si vous ne vous 
souvenez pas du mois) 
 
0. Date de début du traitement…………… 
1. Je ne sais pas 
 
 
F. Si vous êtes actuellement traité par comprimés (ou gélules ou granulés) de 
Pentasa, Rowasa, Dipentum, Fivasa ou Salazopyrine, quelle dose prenez-vous 
chaque jour ? 
 
dose : (grammes/jour)………………… 
 
 
G. Avez-vous eu des coloscopies entre le 01/05/2004 et la réception de ce courrier: 
 
0. non 
1. oui, une seule coloscopie 
2. oui, 2 coloscopies 
3. oui, plus de 2 coloscopies 
 
 
Concernant les coloscopies réalisées entre le 01/05/2004 et la réception de ce courrier, 
merci de répondre aux questions suivantes dans le tableau ci-joint en mettant une 
croix dans la (ou les) case(s) correspondant à votre cas, comme dans l’exemple. 
 
 
Merci de nous renvoyer ce questionnaire rempli à l’aide de l’enveloppe T ci jointe. 
Vous pouvez également nous adresser ces éléments par fax au ………...  
Si vous avez des difficultés ou que vous préférez répondre à ce questionnaire par téléphone, 
n’hésitez pas à nous appeler sur le numéro suivant : 01-49-28-22-02 afin que l’on puisse le remplir 
avec vous par téléphone. 
 
Afin de préserver votre anonymat, toutes les données vous concernant seront rendues anonymes 
 
En vous remerciant du temps que vous nous avez consacré, soyez assuré(e), Madame, Monsieur, 
de nos sentiments les plus cordialement dévoués.  
 
       L’équipe de  l’étude SECCIRC 
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S ECC I RC  
ENQUETE DE PRATIQUE DE LA COLOSCOPIE DANS LES MICI 
NUMERO D’ANONYMAT 
 
 
  Exemple Coloscopie N°1 Coloscopie N°2Coloscopie N°3Coloscopie N°4 
Date de la coloscopie 
*   
 
jj/mm/aaaa 01/05/2004
        
Hôpital "nom de l'hôpital" X 
        
examen réalisé dans un autre établissement  
(autre hôpital ou cabinet privé) 
 
        
Lieu de la coloscopie 
 je ne sais plus 
         
poussée  
        
bilan avant changement de traitement X 
        
dépistage  
        
Raison de l'examen 
je ne sais pas  
        
PEG: Kleanprep, Fortrans, Colopeg, Moviprep, 
Biopeg 
X 
        
Xprep  
        
Fleetphosphosoda  
        
Type de préparation 
je ne sais pas  
        
 
* Pour la date des coloscopies, si vous ne vous rappelez pas la date précise, merci de nous donner l’année et le mois 
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